STRATUM Data is "Clearly Good News... Could Drive Stock Higher" - Cantor Fitzgerald Bullish on Arcutis Biotherapeutics (ARQT) Following Phase 3 Readout
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $50.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
